Femasys Inc. has announced a significant milestone in its global expansion efforts with its first commercial entry into Europe. The company secured an order valued at approximately $400,000 USD for its FemBloc Permanent Birth Control in Spain, marking the country as the first to establish a distribution partnership. FemBloc is a groundbreaking non-surgical permanent contraceptive that uses a patented delivery system to safely block fallopian tubes, eliminating the risks associated with surgical sterilization. This development follows a collaboration with Spanish partners Comercial Medico Quirúrgica and Durgalab, who are poised to navigate both public and private healthcare systems to implement FemBloc efficiently. Femasys is focused on scaling production to meet the anticipated demand as interest grows across Europe.